

Special Issue

Advances in Oral Cancer: From Pathology to Treatment

Message from the Guest Editor

Oral squamous cell carcinoma is the most common head and neck malignancy, characterized by high invasive capacity, lymph node metastasis, and high recurrence rate. Indeed, despite recent diagnostic and therapeutic advances, the prognosis is poor, showing a 5-year survival rate of 50–60%. Even if the recently released 8th edition of the AJCC Staging Manual has introduced several modifications improving the prognostic prediction accuracy, it is still necessary to find new prognostic markers in order to better stratify those patients who could benefit from more specific therapies. Moreover, despite the classic subject affected by OSCC, a growing incidence among younger subjects mainly linked to HPV infection has been reported in recent years. The improved understanding of the mechanisms involved in cancer development may lead to the identification of new potential therapeutic targets, allowing the use of novel strategies to the clinical treatment of OSCC. The recent advances in clinical studies evaluating treatment strategies and new therapies need further research.

Guest Editor

Prof. Dr. Andrea Santarelli

Department of Clinical Specialistic and Dental Sciences, Marche Polytechnic University, Via Tronto 10/A, 60126 Ancona, Italy

Deadline for manuscript submissions

closed (31 December 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/57085

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)